SB 01

Drug Profile

SB 01

Alternative Names: 6-Methoxy-3-(3',4',5'-trimethoxybenzoyl) indole; BPR 0L075; DBPR104; SB01; SCB 01A

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator National Health Research Institutes
  • Developer SynCore Biotechnology
  • Class Antineoplastics; Indoles; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Head and neck cancer
  • No development reported Solid tumours

Most Recent Events

  • 12 Jan 2017 SynCore Biotechnology plans a phase II trial for Head and neck cancer (Inoperable/Unresectable, Metastatic disease, Recurrent, Second-line therapy or greater) in Taiwan (IV, Infusion) (NCT03020823)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in Taiwan (Parenteral, Injection)
  • 01 Sep 2015 Phase-II clinical trials in Head and neck cancer (Recurrent, Metastatic disease, Second-line therapy or greater) in Taiwan (Parenteral) (NCT02488629)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top